• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Chennai , Nov. 3

SERUM Institute aims to launch a single vaccine for five indications (pentavalent vaccine) in September-October 2005. Currently, the vaccine is being put through clinical trials.

The company's Director-Sales, Mr S.S. Chandrababu, on Wednesday said that the pentavalent vaccine would provide protection against Diphtheria, Pertussis, Tetanus (DPT), Hepatitis-B and Haemophilus Influenza type B (HIB).

A single vaccine that covers more than one indication reduces the number of shots children have to take. Mr Chandrababu said that Serum Institute would also introduce a vaccine to cover four indications (DPT and Hepatitis-B) next year.

Serum Institute on Wednesday formally launched its new rabies vaccine, Rabivax, in Chennai. Rabivax is a Human Diploid Cell (HDC) vaccine that has been priced at Rs 293 a dose.

More Stories on : Announcements | Pharmaceuticals | Health | Tamil Nadu

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Audi to launch 7 new models

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line